我们调查了12周食用蚕蛹提取物(SWP)对骨骼肌质量相对较低的中老年人进行定期低强度运动的肌肉质量和力量的疗效和安全性。
一项随机双盲安慰剂对照试验。
该研究对54名骨骼肌质量(SMM)相对较低(64.4±6.1岁;体重指数,23.8±2.4kg/m2)。
参与者被随机分配到两组中的一组:1000毫克SWP/天加上定期运动(SWP组,n=27)或安慰剂加定期运动(安慰剂组,n=27)。所有参与者都被要求进行30-60分钟/天的步行,≥3天/周,持续12周。主要结果是膝关节伸展/屈曲强度(Nm),以60°/s的速度测量。次要结果包括身体成分,生物标志物(肌酸激酶和肌酐),握力,和生活质量问卷。
在12周内,与安慰剂组相比,意向治疗(ITT)和符合方案(PP)分析均显示SWP对膝关节强度没有显着影响。另一方面,与安慰剂组相比,SWP组的右手握力增加了1.94kg(95%CI:0.08-3.79;p=0.041),左手握力增加了1.83kg(0.25-3.41;p=0.024)。12周后。此外,在PP人群中,SWP组显示右手握力增加2.07kg(0.15-3.98;p=0.035),左手握力为2.21kg(0.60-3.83;p=0.008),持续12周。然而,这项研究导致未能检测到身体成分的显著差异,生物标志物,生活质量问卷,身体活动,和小组之间的热量摄入。SWP组的参与者均未出现任何重大不良事件。在安慰剂组中,两名参与者经历了荨麻疹和过敏性副作用,导致他们退出研究,两个人表现出肝酶水平升高和舒张压升高,分别在12周。
SWP,除了低强度运动,可能会增强SMM相对较低的中老年人的握力。未来的研究需要在更长的时间内使用大样本来验证我们的发现。该试验在clinicaltrials.gov注册为NCT04994054。
We investigated the efficacy and safety of silkworm pupae extract (SWP) consumption for 12 weeks on muscle mass and strength in middle-aged and older individuals with relatively low skeletal muscle mass who do regular low-intensity exercise.
A randomized double-blinded placebo-controlled
trial.
The
study was conducted with 54 participants with relatively low skeletal muscle mass (SMM) (64.4 ± 6.1 years; body mass index, 23.8 ± 2.4 kg/m2).
Participants were randomly assigned to one of two groups: 1000 mg of SWP/day plus regular exercise (SWP group, n=27) or placebo plus regular exercise (placebo group, n=27). All participants were required to engage in 30-60 minutes/day of walking for ≥3 days/week for 12 weeks. The primary outcome was knee extension/flexion strength (Nm), measured at the velocity of 60°/s. Secondary outcomes included body composition, biomarkers (creatine kinase and creatinine), handgrip strength, and quality of life questionnaire.
Both the intention-to-treat (ITT) and per-protocol (PP) analyses revealed no significant impact of SWP on knee strength compared to the placebo group over 12 weeks. On the other hand, the SWP group had significantly greater increases in right-handgrip strength by 1.94 kg (95% CI: 0.08-3.79; p = 0.041) and left-handgrip strength by 1.83 kg (0.25-3.41; p = 0.024) compared to the placebo group in the ITT population, after 12 weeks. Moreover, in the PP population, the SWP group revealed an even greater increase in right-handgrip strength by 2.07 kg (0.15-3. 98; p = 0.035) and left-handgrip strength by 2.21 kg (0.60-3.83; p = 0.008) for the 12-week period. However, this
study resulted in a failure to detect significant differences in the body composition, biomarkers, quality of life questionnaire, physical activity, and caloric intake between the groups. None of the participants in the SWP group experienced any significant adverse events. In the placebo group, two participants experienced urticaria and allergic side effects, leading to their withdrawal from the
study and two exhibited elevated levels of liver enzyme and increased diastolic blood pressure, respectively at 12 weeks.
SWP, in addition to low-intensity exercise, may enhance handgrip strengths in middle-aged and older adults with relatively lower SMM. Future studies need to use a large sample size over longer periods to validate our findings. This
trial was registered at clinicaltrials.gov as NCT04994054.